Difference between revisions of "Paroxetine-tranylcypromine"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* Then the administration of tranylcypromine can be started in low dosage of 20 mg/day for one week.
 
* Then the administration of tranylcypromine can be started in low dosage of 20 mg/day for one week.
 
* After this week the dosage of tranylcypromine can be increased if necessary.
 
* After this week the dosage of tranylcypromine can be increased if necessary.
| info =
+
| caveat =
* A switch from paroxetine to tranylcypromine is not obvious, given the necessary prolonged wash-out period in this case.
+
{{caveSS}}
* Occurrence of serotonin syndrome is reported when a wash-out period is not considered.}}
+
}}

Revision as of 16:55, 20 July 2009

paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from paroxetine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop paroxetine

Depending on the condition of the patient, there are two scenarios possible:

  1. Gradually reduce dosage of paroxetine to a maximum of 20 mg/day, and then stop administration abruptly.
  2. Phase out paroxetine from 20 mg/day, to 10 mg/day for one week, and then stop administration abruptly.
Eenrichtingbord.png Start tranylcypromine
  • Both scenarios are followed by a wash-out period of one week.
  • Then the administration of tranylcypromine can be started in low dosage of 20 mg/day for one week.
  • After this week the dosage of tranylcypromine can be increased if necessary.
Letopbord.png Cave


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.